COMMUNIQUÉS West-GlobeNewswire

Breakthrough San Diego Clinic Uses Cutting-Edge NUCCA Technique to Reverse Chronic Pain and Restore Quality of Life — Without Drugs or Surgery
24/09/2025
San Diego-based Origin Modern Health & Wellness uses powerful, gentle root cause care, reconnecting individuals to their body’s potential SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- As millions of Americans [...]
Medicovestor, Inc. Wins First Place at the Next Star North America Biomedical Special Competition in Boston, part of the 2025 Entrepreneur Next Star Million Prize Global Challenge
24/09/2025
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Medicovestor, Inc., a biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) for cancer treatment, announced today that it has been awarded First [...]
La Financière de Tubize renforce son expertise dans le domaine biopharma en nommant 2 nouvelles administratrices
24/09/2025
Depuis la nomination de Bruno Holthof comme président du conseil d'administration de la société en avril 2025, le conseil d’administration de la société poursuit le renforcement de son expertise dans le domaine [...]
Financière de Tubize strengthens its expertise in the biopharma field by appointing 2 new directors
24/09/2025
Since the appointment of Bruno Holthof as Chairman of the Board of Directors of the company in April 2025, the company's board has continued to strengthen its expertise in the biopharma field. This aims to best support [...]
Pluristyx and Solesis Announce Strategic Collaboration to Advance Organoid and Cell Therapy Solutions
24/09/2025
SEATTLE and TELFORD, Pa., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pluristyx, Inc. and Solesis, LLC today announced the signing of a Memorandum of Understanding (MOU) establishing their strategic collaboration. The primary [...]
Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management
24/09/2025
PALO ALTO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
The Association of American Physicians and Surgeons (AAPS) Supports Course Correction on Autism
24/09/2025
TUCSON, Ariz., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In a joint appearance, President Donald Trump, HHS Secretary Robert F. Kennedy, Jr., NIH Director Jay Bhattacharya, FDA Commissioner Marty Makary, and CMS Director [...]
Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations
24/09/2025
Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR [...]
Booking Health Expands Access to Stage 4 Cancer Treatment in Germany
24/09/2025
Langenfeld, Germany, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Booking Health , a leading medical travel facilitator, has announced the expansion of its oncology services to improve international access to advanced stage 4 [...]
EUROBIO SCIENTIFIC: RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025
24/09/2025
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025 Revenue up 10% to €80.7 million Proprietary products account for 36% of revenue 42% of revenue generated outside France 2025 results impacted by the transfer of [...]
Eurobio Scientific : résultat du 1er semestre 2025
24/09/2025
RESULTAT DU 1 ER SEMESTRE 2025 Chiffre d’affaires en croissance de 10% à 80,7 M€ les produits propriétaires atteignent 36% du CA la part du CA hors France est de 42% Résultats 2025 impacté par le transfert de la [...]
Guerbet : Résultats semestriels 2025 : Chiffre d’affaires du 1er semestre : 387,8 M€, en retrait de 5,4% à TCC et périmètre comparable principalement en lien avec la baisse d’activité en France
24/09/2025
Résultats semestriels 2025 Activité et rentabilité Chiffre d’affaires du 1 er semestre : 387,8 M€, en retrait de 5,4% à TCC 1 et périmètre comparable 2 , principalement en lien avec la baisse d’activité en France La [...]
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France
24/09/2025
H1 2025 results Activity and profitability H1 revenue: €387.8 million, down 5.4% at CER 1 and on a like-for-like basis 2 , mainly due to the decline in activity in France Restated EBITDA margin 3 came out at 12.9%, [...]
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
24/09/2025
SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and [...]
LUKE Calls for National Partnerships to Help America’s Heroes Flourish
24/09/2025
NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- As the American Association of Christian Counselors (AACC) World Conference in Nashville opens, LUKE Holdings, Inc. (“LUKE”), a trusted leader in healthcare staffing [...]
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
24/09/2025
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be [...]
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
24/09/2025
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to [...]
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
24/09/2025
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose [...]
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
24/09/2025
IMDX to host symposium on Wednesday, September 24 th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting Presenting on GraftAssureIQ at [...]

Pages